洛铂、顺铂分别联合足叶乙甙治疗老年小细胞肺癌对照研究.pdf

《洛铂、顺铂分别联合足叶乙甙治疗老年小细胞肺癌对照研究.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、258vo1．21No．4武警后勤学院学报(医学版)第21卷第4期Apr．2012JournalofLogisticsUniversityofCAPF(MedicalSciences)2012年4月doi：lO．3969~．issn．2095—3720．2012．04．O11洛铂、顺铂分别联合足叶乙甙治疗老年小细胞肺癌对照研究齐晓倩，魏长宏，武贵存。，高柯，杜晓杰(1．山东省公安消防总队医院，山东济南250102；2．武警山东总队医院肿瘤血液科，山东济南250014)摘要：【目的】评估洛铂(1obaplatin，LB

2、P)联合足叶乙甙(etoposide，VP一16)与顺铂(cisplatin，DDP)联合足叶乙甙治疗老年小细胞肺癌的近期疗效和毒性反应。【方法156例老年小细胞肺癌(smallcelllungcancer，SCLC)患者随机分为洛铂联合足叶乙甙的LE组(28例)和顺铂联合足叶乙甙的EP组(28例)。21d为1周期，连用2个周期后评价近期疗效。每周评估毒性反应。【结果】LE组和EP组有效率(RR)分别为71％和68％，疾病控制率(DCR)分别为89％和86％，均无显著性差异fP>0．05)。两组骨髓抑制无显著性差异(

3、P>0．05)；消化道反应LE组和EP组分别为21％和50％，有显著性差异(P<0．05)。【结论】LE和EP均为治疗老年SCLC的有效方案，疗效相当，LE组消化道反应较EP组轻，故LE组患者耐受性更好，特别适合老年患者和曾接受过DDP联合化疗方案的复治患者。关键词：小细胞肺癌；老年人；足叶乙甙；洛铂；顺铂【文章编号】2095—3720(2012)04—0258—04【中图分类号】R64【文献标识码】AArandomizedcomparativestudyofIobaplatinandcisplatincombine

4、dwithetoposideforsmallcelllungcancerinelderpatientsQIXiao-qian，WEIChang-hong，WUGui-cun，GAOKe，DUXiao-jie(TheFireCorpsHospitalofShandongProvince，Jinan250102，China)Abstract：【Objective】Toobservetheshort—termclinicaleficacyandthesideeffectsofLE(1obaplatinandetoposid

5、e)andEP(cisplatinandetoposide)regimensforadvancedsmallcelllungcancer(SCLC)inelderpatients．【Methods】Atotalof56easesofadvancedsmallcelllungcancerwererandomizedintoLEgroup(28patients)andEPgroup(28patients)accordingtothehospitaldiagnosis．Twoprogramswererepeatedever

6、y21daysand2cycles．Theshort—termclinicaleficacyandthesideeffectsoftwogroupswereevaluatedeveryweek．【Results]Theresponserateinexperimentgroupandcontrolgroupwere71％and68％respectively，anddiseasecontrolratewere89％and86％respectively．whereasalltheobservedeffectshadnosi

7、gnificance(P>0．05)．Theside—effectsweremainlymyleosuppressionwithnostatisticdiferences(P>0．05)．However．thesideeffectsofgastrointestinalreactioninthetwogroupswere21％and50％respectively，withobviousstatisticdiference(P<0．05)．【Conclusion】LEandEPregimenshavesimilartot

8、alefectiverateandsideeffectsinpatientswithSCLC．Thereisnosignificantsurvivaladvantagefortheprogramoflobaplatinandetoposideascomparedwiththeonewithcisplatinandetoposide，butthe